Sickle Cell Disease: Pipeline Insights 2018 - Detailed Analysis of 55+ Products Along With 50+ Companies Involved - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Sickle Cell Disease - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report outlays comprehensive insight of the present scenario and growth prospects across Sickle Cell Disease.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 55+ products along with 50+ companies involved.
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
Products covered by PhasePhase III, Phase II, Phase I and IND Pre-clinical and Discovery Unknown Stage Inactive (Dormant and Discontinued)
Scope of the ReportProvides an overview of therapeutic pipeline activity for Sickle Cell Disease across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of Sickle Cell Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Sickle Cell Disease
Key Topics CoveredSickle Cell Disease Overview Causes Symptoms Pathophysiology Types of Sickle Cell Disease Diagnosis Treatment Research for Future Treatment Pipeline Therapeutics (Clinical Products) Pipeline Therapeutics (Non-Clinical Products) Pipeline Therapeutics (Inactive Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Crizanlizumab: Novartis Product Description Research and Development Product Development Activities (The list continues) Mid Stage Products (Phase II) Comparative Analysis Early Stage Products (Phase I and IND) Comparative Analysis Pre-clinical and Discovery Stage Products Comparative Analysis Unknown Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant Drugs Comparative Analysis Discontinued Drugs Comparative Analysis Appendix
Companies MentionedAcceleron ArQule Astellas AstraZeneca Bioverativ Bluebird Bio Bristol-Myers Squibb Centocor Complexa CRISPR Therapeutics CSL Behring Editas Medicine Eli Lilly Genethon Gilead Sciences Glycomimetics HemaQuest Pharmaceuticals Hillhurst Biopharmaceuticals Icagen Imara Incyte Ironwood La Jolla Leo Pharma Modus Therapeutics Molecules for Health Novartis NuvOx Pharma Orphagen Pharmaceuticals Pfizer Prolong Pharmaceuticals ReveraGen Sancilio & Company Sanofi TRF Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tzsd2k/sickle_cell?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006612/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 03:22 PM/DISC: 06/05/2018 03:22 PM